Search

Displaying results 6741 - 6750 of 10000 in total
  1. Drug

    GS030-DP

    go.drugbank.com/drugs/DB17847
    Investigational

    It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701] … GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa.

  2. Drug

    Huperzine B

    go.drugbank.com/drugs/DB03348
    Experimental

    Huperzine B is a novel acetylcholinesterase inhibitor.

  3. Drug

    alpha-Pyrrolidinononanophenone

    go.drugbank.com/drugs/DB05531
    Investigational

  4. Drug

    Influenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16917
    Approved

    Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  5. Drug

    SB-743921

    go.drugbank.com/drugs/DB05546
    Investigational

  6. Drug

    Retaspimycin

    go.drugbank.com/drugs/DB05626
    Investigational

  7. Drug

    Efavaleukin alfa

    go.drugbank.com/drugs/DB16149
    Investigational

    It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease). … Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker.

    Synonyms: Fc il-2 mutein fusion protein (amg-592)
  8. Drug

    GC5107

    go.drugbank.com/drugs/DB17604
    Investigational

    GC5107 is an investigational intravenous immunoglobulin. It is marketed as IVIG-SN.

  9. Drug

    Danvatirsen

    go.drugbank.com/drugs/DB14825
    Investigational

    Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).

  10. Drug

    Bisphosphocin Nu-3

    go.drugbank.com/drugs/DB16015
    Investigational

    Bisphosphocin Nu-3 is under investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus).